Skip to content

A Real-World Cohort Study on the Effect of Shuxian Yikang Series Formulae in Treating Graves' Hyperthyroidism

A Real-World Cohort Study on the Effect of Shuxian Yikang Series Formulae in Treating Graves' Hyperthyroidism

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2024000726
Enrollment
Unknown
Registered
2024-11-22
Start date
2024-11-25
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Graves' diease

Interventions

Non-exposed group:No use of the series of herbal formulas for liver detoxification and hyperactivity suppression.
Soothing liver Yikang series prescription group:Use the Shugan Yikang series formula

Sponsors

Jiangsu Provincial Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Patients with Graves hyperthyroidism aged 18-70 years of age regardless of gender (initial onset relapse after drug withdrawal); (2) The syndrome of liver fire exuberant; (3) Voluntary signing of informed consent.

Exclusion criteria

Exclusion criteria: (1) Patients with pregnancy plans pregnancy or lactation (2) Patients with severe heart liver kidney brain diseases and psychosis such as aspartate aminotransferase (AST) and/or Alt (ALT) elevation beyond the reference range (AST > 138U/L ALT > 210U/L) =3 times neutrophil count is zero Value (N) < 1.5*10 9 /L etc. (3) hyperthyroidism crisis patients; (4) various thyroiditis; (5) Allergic constitution and allergic to the test drug; (6) Use of other iodine-rich drugs such as amiodarone

Design outcomes

Primary

MeasureTime frame
tsh;ft3;tt4;ft4;tt3;

Secondary

MeasureTime frame
Reduction of methimazole;TCM symptom score quantified;Thyroid size nodules change;trab;Relapse rate after discontinuation;Exophthalmic remission rate;tpoab;Urine iodimetry;tgab;

Countries

China

Contacts

Public ContactYu Jiangyi

Affiliated Hospital of Nanjing University of Chinese Medicine

yujiangyi2007@163.com13951704703

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026